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Abstract
Introduction: One of the therapeutic essentials in severe sepsis and septic shock is an adequate fluid
replacement to restore and maintain circulating plasma volume, improve organ perfusion and nutritive
microcirculatory flow. The type of solution to be used as a fluid replacement remains under discussion. The aim
of the study was to evaluate the effects of clinically used fluid replacement solutions on renal function and
inflammatory response.
Methods: A total of 23 anesthetized and ventilated female German Landrace pigs were investigated over 19 hours
using a two-hit model that combined hemorrhagic and septic shock. The septic shock was induced using an
Escherichia coli laden clot placed into the abdominal cavity. Infusions of 6% hydroxyethylstarch 130/0.42 in acetate
(6% HES 130), 4% gelatin in acetate (4% gelatin) and 10% hydroxyethylstarch 200/0.5 in saline (10% HES200)
compared to Ringer’s acetate (RAc) were used for fluid replacement to maintain a central venous pressure of 12
mmHg. Ringer’s acetate was also used in the sham-treated group (SHAM).
Results: At study end the cardiac output (10% HES200 143 ± 48 ml/kgBW; 6% HES130 171 ± 47 ml/kgBW; RAc
137 ± 32 ml/kgBW; 4% gelatin 160 ± 42 ml/kgBW), as well as mean arterial pressure did not differ between
groups. N-acetyl-beta-D-glucosamidase was significantly higher in the hydroxyethylstarch 200 (157 ± 115 U/g
creatinine; P < 0.05) group compared to hydroxyethylstarch 130 (24 ± 9 U/g creatinine), Ringer’s acetate (2 ± 3
U/g creatinine) and SHAM (21 ± 15 U/g creatinine) at the study’s end. Creatinine significantly increased by 87 ±
84 percent of baseline in the 10% HES200 group compared to RAc and 6% HES130. We demonstrated in the
histology of the kidneys a significant increase in osmotic-nephrosis like lesions for 4% gelatin compared to RAc,
6% HES130 and SHAM. Urine output was lowest in the 10% HES200 and 4% gelatin group, however not
significantly.
Interleukin(IL)-6 levels were significantly elevated in the 10% HES200 group (3,845 ± 1,472 pg/ml) two hours after
sepsis induction compared to all other groups (6% HES130 1,492 ± 604 pg/ml; RAc 874 ± 363 pg/ml; 4% gelatin
1,623 ± 1,242 pg/ml).
Conclusions: Despite similar maintenance of macrocirculation 6% hydroxyethylstarch 130/0.42 and Ringer’s acetate
significantly preserve renal function and attenuate tubular damage better than 10% hydroxyethylstarch 200/0.5 in
saline.
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Introduction
In severe sepsis and septic shock, adequate fluid replace-
ment is one of the essential therapeutic requirements to
restore and maintain circulating plasma volume in order
to improve organ perfusion and nutritive microcircula-
tory flow [1]. It has been shown that early goal-directed
fluid resuscitation in patients with severe sepsis and sep-
tic shock is associated with improved outcome [2].
Recently, updated international guidelines indicate that
there is no robust evidence favoring either colloids or
crystalloids for fluid replacement in patients with sepsis
or septic shock [3].
The question of which type of solution to use as a fluid
replacement remains controversial [4]. In Europe, mostly
artificial colloid solutions are used on the basis of gelatin
and hydroxyethyl starches (HES). Adverse effects of col-
loid administration on renal function have spurred
ongoing research into the pathological mechanisms [5].
In critical ill patients, acute renal dysfunction fre-
quently deteriorates to renal failure due to hypovolemia,
hypoxia, hypoperfusion and toxicity of drugs (for exam-
ple, anti-infectives), as well as endothelial damage indu-
cing pro-inflammatory response finally resulting in
organ dysfunction. Thus, the evaluation of colloid asso-
ciated effects in this context is difficult. Interestingly,
the data on gelatin are limited.
Schortgen and colleagues showed that in severe sepsis
and septic shock patients, there was no survival benefit
and a higher rate of renal failure when using 6% HES
200/0.6-0.66 as compared to gelatin [6]. The negative
impact of 10% HES 200/0.5 as compared to modified
Ringer’s lactate (RL) on renal function in severe septic/
septic shock patients was also demonstrated in a recent
randomized VISEP (efficacy of fluid substitution and
insulin therapy in severe sepsis) trial [7].
A large prospective observational study including over
3,000 critically ill patients showed that in a length of
ICU stay of more than 24 hours, sepsis, heart failure
and haematological cancer were all significantly asso-
ciated with the need for dialysis or haemofiltration ther-
apy, but fluid replacement with HES was not [8].
So far, almost all colloids are dissolved in 0.9% NaCl
or in 5% glucose. The use of these colloids may be asso-
ciated with undesirable electrolyte disturbances or even
acid-base derangements [9]. In experimental septic
shock, fluid resuscitation using a balanced HES prepara-
tion resulted in significantly improved survival as com-
pared with saline-based resuscitation [10].
Recent developments include the introduction of new
formulations and newly available HES and gelatin pro-
ducts. HES in acetate with a low molecular weight (130
kD) and other balanced solutions have been developed.
The profiles of these solutions appear to be useful for
clinical situations where large amounts of fluid replace-
ment solutions are administered [11].
Previously, we found that 10% HES 200/0.5 was asso-
ciated with a significantly elevated inflammatory
response in tubular monocytes. This pronounced pro-
inflammatory effect of 10% HES 200/0.5 compared with
6% HES 130/0.42 caused more tubular damage than 6%
HES 130/0.42 and RL [12].
Based on our ex vivo experiment we investigated
effects of fluid solutions on renal function and inflam-
matory response in a porcine two-hit model that com-
bines hemorrhagic and septic shock. We selected the
commonly used balanced solutions 6% HES 130/0.42 in
RAc and 4% modified gelatin in RAc, 10% HES 200/0.5
in 0.9% NaCl compared to Ringer’s acetate (RAc).
Materials and methods
Animals
Female German Landrace pigs (n = 23; mean 28.1 ± 1.7
SD kg body weight (BW)) were used and standard proce-
dures for laboratory animal care were followed. This
study was approved by the institutional and local com-
mittee on the care and use of animals (Thüringer Lande-
samt für Lebensmittelsicherheit und Verbraucherschutz,
Bad Langensalza, Germany).
General anesthesia and surgical procedures
Animals were premedicated via intramuscular adminis-
tration of ketamin and midazolam. Thereafter, general
anesthesia was induced by intravenous injection of pro-
pofol (3 to 4 mg/kg BW) and the animals were orally
intubated and placed in the supine position. General
anesthesia was maintained with an infusion of propofol
and sufentanil. Controlled pressure mode ventilation was
chosen to ventilate the animals with an inspiratory oxy-
gen fraction of 0.4, an inspiratory/expiratory ratio of 1:2,
positive end-expiratory pressure (PEEP) set to 5 and a
tidal volume of 8 to 10 ml/kg BW. Respiratory rate was
set with the aim to maintain a PaCO2 of 35 to 46 mmHg.
The core body temperature was kept at above 37.5°C
with the use of a warming blanket. A transpulmonary
thermodilution catheter, central venous line and the pul-
monary artery catheter were placed as we described in
detail in former papers [4]. None of the infusion systems
were heparinized. In all animals, a midline laparotomy
was performed and the left renal artery was exposed and
a Transonic Doppler flow probe (Transonic Systems,
Ithaca, NY, USA) was placed around the vessel to mea-
sure blood flow of the left renal artery (RBF).
Escherichia coli fibrin clot
In this model, we used an Escherichia coli laden clot to
induce septic shock. We used 7 to 9 × 109 colony
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forming units (CFU) per kg/BW. The clot was made
from a sterile solution of porcine fibrinogen (Sigma-
Aldrich Inc., St. Louis, MO, USA) (final volume was
adjusted to the pig’s weight). The clot was formed by
adding thrombin from bovine plasma to the fibrinogen
and E. coli solution and incubating for 30 minutes at
room temperature.
Hemodynamics
All intravascular pressure measurements were refer-
enced to mid-chest level and values were obtained at
end expiration. Mean arterial pressure (MAP), central
venous pressure (CVP), mean pulmonary artery pressure
(MPAP) and pulmonary artery occlusion pressure
(PAOP) were recorded from calibrated pressure transdu-
cers (Edwards Lifesciences, Irvine, CA, USA) and values
obtained at end-expiration.
Intrathoracic blood volume (ITBV) was calculated by
the mean transit time approach (transpulmonary thermo
dilution technique) using a PiCCO® System (PULSION
Medical Systems SE, Munich, Germany).
Cardiac output (CO) was determined by thermodilu-
tion with a CO computer (Vigilance®; Edwards Life-
sciences Ltd, Newbury, UK).
Systemic oxygen delivery (DO2), oxygen extraction
ratio (OE) and consumption (VO2) were calculated from
hemoglobin, oxygen saturation, PaO2 and cardiac output
according to standard formulae.
Laboratory
Blood gas analyses were measured using a standard
blood gas oximetry system (ABL 625; Radiometer,
Copenhagen, Denmark) with a co-oximeter. Sodium,
potassium, chloride, creatinine and hematocrit (Hct)
were determined using standard laboratory techniques.
We calculated the anion gap with the formula: anion
gap = ((Na+)+(K+))-((Cl-)+(HCO3
-)).
Colloid osmotic pressure (COP) was analyzed using a
membrane colloid oncometer with a 20 kD semi-perme-
able membrane (BMT 921, Delta-Pharma, Pfullingen,
Germany). From urine specimen, N-acetyl- beta-D-glu-
cosamidase (NAG; analyzed by a spectrophotometric
method; Hoffmann-La Roche, Basel, Switzerland), an
approved sensitive marker of lysosomal tubular damage
[10], was measured. Creatinine clearance was measured
as an estimate of glomerular filtration rate (ClCrea =
Ucrea × Uvol/Pcrea × duration of urine collection per-
iod; where Ucrea = urine creatinine concentration; Uvol
= urine volume during the collection period; Pcrea =
serum creatinine concentration). The duration of urine
collection period was 240 minutes.
Cumulative fluid balance was calculated as fluid input
minus urinary output during the entire study period.
Body weight of animals was measured directly before
experimentation.
Flowmetry
Left renal arteries were identified close to their origins
at the aortas. A pre-calibrated ultrasonic transit time
flow probe (Transonic Systems Inc., Ithaca, NY, USA)
was placed around the vessels and connected to an
ultrasound blood flow meter (T207; Transonic Systems
Inc.).
Cytokines
Levels of interleukin 6 (IL-6), interleukin 10 (IL-10) and
tumor necrosis factor alpha (TNF-a) in plasma were
assessed by an enzyme-linked immunosorbent assay
using commercially available kits specific for pigs (IL-6;
IL-10; TNF-a: BioSource, Solingen, Germany). Measure-
ments were made according to the manufacturer’s
guidelines and blood samples were collected additionally
two and four hours after sepsis induction.
Histological analysis
Biopsies of the kidney were taken directly after euthana-
sia of the animals, fixed in 4% formaldehyde and
embedded in paraffin. Sections (4 μm) were cut and
stained with hematoxylin and eosin (H&E). Renal mor-
phology was assessed semiquantitatively using the fol-
lowing four criteria of tubulointerstitial renal injury:
acute tubular necrosis (ATN), that is, dilatation of tubuli
with flattening or loss of the tubular epithelium, intersti-
tial bleeding (IBl), glomerulo sclerosis (GSl) and osmo-
tic-nephrosis like lesions (OL) of the tubuli (see also
Additional files 1, 2, 3). One experienced investigator
blinded to the groups scored each variable using a semi-
quantitative scoring system (0 to 4) for each criterion in
20 randomly sampled visual fields per animal: 0 (absent),
1 (0 to 25%), 2 (25 to 50%), 3 (50 to 75%) or 4 (more
than 75%) [10].
Experimental protocol
During the surgical procedure, animals received 10 ml/
kg BW/h RAc (Serumwerke Bernburg AG, Bernburg,
Germany). Hemorrhagic shock was induced by bleeding
the animals via the carotid artery catheter. Animals
were bled until half of the baseline MAP was reached,
resulting in a blood loss of 32.8 ± 3.8 ml/kg BW per
animal. Hemorrhagic shock was maintained for 45 min-
utes. Thereafter, animals were randomly allocated to
receive either fluid therapy with RAc (n = 5), 4% gelatin
in RAc (4% gelatin) (Gelafusal®, Serumwerke Bernburg
AG, Bernburg, Germany) (n = 5), 6% HES with a mole-
cular weight of 130 kD and a molar substitution of 0.42
in RAc (HES 130) (Vitafusal®, Serumwerke Bernburg
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AG, Bernburg, Germany) (n = 5), 10% HES with a mole-
cular weight of 200 kD and a molar substitution of 0.5
in 0.9% sodium chloride (HES 200) (Infukoll®, Serum-
werke Bernburg AG AG, Bernburg, Germany) (n = 5),
compared to a non-shock, sham-operated control group
(SHAM, n = 3) receiving RAc. Fluid replacement was
performed while maintaining baseline MAP for six
hours. In addition, four hours after cessation of the
hemorrhagic shock, the blood collected during hemor-
rhagic shock was retransfused.
Six hours after hemorrhagic shock, the infected clot
was placed into the abdominal cavity to induce septic
shock. SHAM group received a non-infected clot.
Two hours after the induction of septic shock, the
hemodynamic treatment scheme aimed at maintaining a
CVP of 12 mmHg was initiated. Fluid therapy during
this second shock was the identical randomized solution
that was administered during hemorrhagic shock; hence,
each animal received only one study solution. CVP was
measured continuously and a gradual continuous fluid
resuscitation was carried out. After induction of sepsis,
animals were treated for another 12 h. Measurements
were performed at baseline, before induction of septic
shock (6 h after resolution of hemorrhagic shock) and
12 h after induction of septic shock (Figure 1).
Statistical analysis
Data were analyzed using SPSS 16.0 for Windows (IBM
Statistics, Ehningen, Germany) and all results are pre-
sented as mean ± standard deviation (SD). After verify-
ing normal data distribution (skewness < 1.5) [13],
effects of fluid replacement solution were statistically
analyzed by analysis of variance (ANOVA) for repeated
measurements. Bonferroni’s correction was applied for
multiple comparisons, following ANOVA for each single
time point. Differences were considered significant at P
< 0.05. Data are presented at baseline (BL), 6 h after
hemorrhagic and before septic shock (SL) and 12 h after
sepsis induction (12 h sepsis).
A three-fold increase in beta-NAG was regarded as
clinically relevant. A total sample size of at least 23
animals was necessary in order to achieve a power of at
least 80%.
Results
In all animals, study protocol was completed. All ani-
mals reached the predefined target in hemorrhagic
shock and fluid resuscitation. There were no differences
in blood loss between the groups.
Hemodynamics
Hemodynamic parameters are summarized in Table 1.
Baseline values were comparable in all groups. Twelve
hours after sepsis induction CO, as well as MAP, CVP
and PAOP, did not differ between groups. MPAP
increased significantly in the HES200 group 12 h after
sepsis induction compared to the RAc, 6% HES130 and
SHAM group (Table 1).
Fluid balance and laboratory
Treatment with RAc led to a significantly higher fluid
input and fluid balance in the RAc group as compared
to all other groups after 12 h of sepsis. The degree of
Hct was similar in all groups at baseline and 12 h after
induction of sepsis (Table 1). COP was significantly
higher in 10% HES200 and 4% gelatin group after 12 h
of sepsis compared to 6% HES130 and RAc (Table 1).
Inflammation
The inflammatory response was enhanced in all septic
groups two hours after sepsis induction. IL-6 (Figure 2)
was significantly higher in the 10% HES200 group com-
pared to all other groups two hours after sepsis induc-
tion and TNF-a increased significantly in the 10%
HES200 group (4,122 ± 1,417 pg/ml; P < 0.05) com-
pared to all other groups (6% HES130 1,199 ± 1,237 pg/
ml; 4% gelatin 1,939 ± 1,691 pg/ml; RAc 1,101 ± 498
pg/ml; SHAM 285 ± 385 pg/ml) two hours after sepsis
induction (Table 2).
IL-10 was significantly elevated after 12 h of sepsis in
the 10% HES200 group compared to 6% HES130, RAc
and SHAM (Table 3).











Figure 1 Schedule of the two-hit model.
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Systemic oxygenation
Results of systemic oxygenation are summarized in
Table 3. SvO2 was comparable at baseline in all groups.
Twelve hours after sepsis induction a significantly lower
SvO2 was observed in the 4% gelatin and 10% HES200
group compared to SHAM (Table 3). Oxygen extraction
ratio (OE) increased significantly in the 4% gelatin and
10% HES200 group compared to SHAM.
Renal function and histology
Electrolyte levels at baseline were comparable in all
groups (Table 4). There were no differences in sodium
levels between groups. Chloride levels were significantly
lower in the 4% gelatin group compared to 10% HES200
and RAc after 12 h of sepsis.
Serum creatinine (as percent of baseline, a negative
value means creatinine is decreasing compared to
baseline) was significantly higher in the 10% HES200
group compared to RAc and 6% HES130 12 h after sep-
sis, and creatinine clearance was significantly lower in
the 10% HES200 and the 4% gelatin group compared to
6% HES130 and SHAM 12 h after sepsis. Urine output
at study end was lower in the 10% HES200 group com-
pared to all other groups (Table 4).
The renal artery flow of the left kidney as percentage
of CO 12 h after sepsis was lower, but not significant, in
the 10% HES200 group compared to all other septic
groups, and significantly lower compared to the SHAM
group (Figure 3).
Baseline values of NAG in urine (in units per gram
creatinine (U/g creatinine)) were comparable in all
groups. Fluid replacement with 10% HES200 led to a
significantly higher NAG at study end compared to 6%
HES130, RAc and SHAM (Figure 4).
Table 1 Hemodynamic parameters and fluid balance
6% HES 130 10% HES 200 RAc 4% gelatin SHAM
HR, bpm Baseline 93 ± 14 91 ± 10 89 ± 12 91 ± 9 98 ± 8
Before sepsis 95 ± 5 96 ± 22 106 ± 20 92 ± 13 98 ± 11
12 h after sepsis 140 ± 19 158 ± 19 ‡ 127 ± 18 151 ± 32 ‡ 93 ± 2
MAP, mm Hg Baseline 90 ± 1 91 ± 2 92 ± 2 91 ± 2 90 ± 1
Before sepsis 91 ± 3 98 ± 8 91 ± 1 93 ± 4 91 ± 3
12 h after sepsis 86 ± 11 70 ± 21 59 ± 5 71 ± 26 96 ± 7
CVP, mm Hg Baseline 7 ± 1 6 ± 1 7 ± 1 7 ± 1 6 ± 1
Before sepsis 6 ± 2 9 ± 2 8 ± 1 8 ± 1 6 ± 1
12 h after sepsis 12 ± 0 12 ± 0 12 ± 0 12 ± 0 12 ± 0
PAOP, mm Hg Baseline 8 ± 1 7 ± 1 8 ± 1 7 ± 1 7 ± 2
Before sepsis 8 ± 2 8 ± 1 10 ± 2 9 ± 2 8 ± 1
12 h after sepsis 11 ± 3 12 ± 1 11 ± 2 10 ± 1 12 ± 1
MPAP, mm Hg Baseline 15 ± 2 16 ± 3 19 ± 1 17 ± 2 18 ± 2
Before sepsis 17 ± 2 20 ± 4 20 ± 1 19 ± 3 21 ± 1
12 h after sepsis 33 ± 9 45 ± 3 *,§,‡ 26 ± 4 41 ± 3 §,‡ 21 ± 4
CO, ml/kgBW Baseline 102 ± 20 109 ± 17 110 ± 15 98 ± 8 110 ± 7
Before sepsis 118 ± 13 133 ± 37 134 ± 28 137 ± 26 126 ± 19
12 h after sepsis 171 ± 47 143 ± 48 137 ± 32 160 ± 42 120 ± 28
Hct, % Baseline 29 ± 1 31 ± 2 28 ± 2 30 ± 3 30 ± 1
Before sepsis 26 ± 1 25 ± 4 26 ± 2 24 ± 4 30 ± 4
12 h after sepsis 28 ± 4 30 ± 4 27 ± 3 25 ± 5 29 ± 4
COP, mm Hg Baseline 11.5 ± 0.9 11.4 ± 2.4 11.1 ± 2.2 11.2 ± 1.0 12.2 ± 1.1
Before sepsis 11.8 ± 1.4 13.6 ± 1.7 9.9 ± 1.1 12.5 ± 0.9 10.9 ± 0.3
12 h after sepsis 10.0 ± 1.7 14.6 ± 1.8 *;§;‡ 8.1 ± 1.5 15.1 ± 1.5 *;§;‡ 10.3 ± 0.4
Fluid input, ml/kg BW Baseline - - - - -
Before sepsis 62 ± 11 45 ± 12 140 ± 41║ 62 ± 14 5 ± 7
12 h after sepsis 213 ± 41 120 ± 35 556 ± 230║ 178 ± 36 110 ± 26
Fluid balance, ml/kg BW Baseline - - - - -
Before sepsis 39 ± 3 28 ± 10 93 ± 25║ 45 ± 17 18 ± 11
12 h after sepsis 149 ± 30 75 ± 33 335 ± 94║ 109 ± 28 68 ± 43
Hemodynamics and Fluid balance in the five groups. Data are presented as mean ± SD at baseline, 6 h after hemorrhagic shock and before sepsis induction
(before sepsis) and 12 h after sepsis induction. BW, body weight; CO, cardiac output; COP, colloid osmotic pressure; CVP, central venous pressure; Hct, hematocrit;
HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PAOP, pulmonary artery occlusion pressure.
* P ≤ 0.05 vs. 6% HES130; § P ≤ 0.05 vs. RAc;;‡ P ≤ 0.05 vs. SHAM; ║P ≤ 0.05 vs. all other groups.
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The histological analyses are presented in Table 5.
They showed a significant increase in OL for 4% gelatin
compared to RAc, 6% HES130 and SHAM. ATN was
significantly higher in 10% HES200 compared to SHAM.
Also IBl was significantly higher in 10% HES200 com-
pared to RAc, 6% HES130 and SHAM. There was a
non- significant increase in GSl in the 10% HES200
group compared to all other groups (Table 5).
Discussion
The most important result of the present study is that
in pigs after hemorrhagic and consecutive septic shock,
6% HES 130/0.42 in RAc and RAc solution are more
effective in preserving renal function. Furthermore, we
demonstrated a significant higher NAG and ATN indi-
cating a more pronounced tubular damage using hyper-
oncotic 10% HES 200/0.5 in 0.9% saline.
Hemodynamics
In macro-circulation there were no differences between
the fluid replacement solutions tested. There were sig-
nificant differences in oxygen extraction and SvO2
between 10% HES200 and 4% gelatin compared to
SHAM and no differences between septic groups.
Time Point























Figure 2 Interleukin 6 levels over study period. Data are presented as mean ± standard deviation in pg/ml at baseline (BL), 6 h after
hemorrhagic shock and before sepsis induction (SL) and 2, 4 and 12 h after sepsis induction * P ≤ 0.05 vs. 6% HES130, RAc und SHAM § = P ≤
0.05 vs. all other groups.
Table 2 TNF-a levels
6% HES 130 10% HES 200 RAc 4% gelatin SHAM
BL 131 ± 57 176 ± 92 172 ± 56 270 ± 214 226 ± 146
Before sepsis 183 ± 93 255 ± 241 125 ± 57 325 ± 210 95 ± 83
2 h after sepsis 1,199 ± 1,239 4,122 ± 1,216* 1,101 ± 498 1,938 ± 1,691 285 ± 386
4 h after sepsis 665 ± 384 2,396 ± 2,656 501 ± 215 746 ± 851 251 ± 364
12 h after sepsis 280 ± 75 673 ± 618 252 ± 64 437 ± 83 400 ± 326
Data are presented as mean ± standard deviation in pg/ml at baseline (BL), 6 h after hemorrhagic shock and before sepsis (before sepsis), 2 h, 4 h and 12 h after
sepsis induction. * P ≤ 0.01 vs. 6% HES130, RAc and SHAM
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Renal function
Sepsis is often associated with impaired renal function.
The effect of HES infusion on renal function in sepsis
patients has spurred ongoing research on the underlying
pathology.
Schortgen and colleagues showed HES to be an inde-
pendent risk factor for acute renal failure in severe sep-
sis [6]. The methodology of this study has been
questioned, although it was randomized and controlled
[9,14]. Recently, in a German multicenter randomized
controlled trial (efficacy of fluid substitution and insulin
therapy in severe sepsis (VISEP) study), it was shown
that the use of 10% HES 200/0.5 compared with lactated
Ringer’s solution (RL) in patients with severe sepsis or
septic shock is associated with an increased need for
renal replacement therapy. Furthermore, the cumulative
dosage of 10% HES200/0.5 was significantly correlated
with the need for renal replacement therapy [7]. In con-
trast, a recent large prospective observational study of
over 3,000 critically ill patients, showed that in those
patients with an ICU stay of more than 24 hours, sepsis,
heart failure and hematological cancer were all signifi-
cantly associated with the need for dialysis or hemofil-
tration therapy, but fluid replacement with HES was not
[14]. Comparing this result with the data of the VISEP
study, one important difference is the total amount of
administered HES. In the VISEP study, patients received
HES for up to 21 days with a median cumulative dose
of 70.4 ml/kg (interquartile range: 33.4 to 144.2 ml/kg),
whereas in the observational study, the median total
amount of HES per patient was lower (1,000 ml, inter-
quartile range: 500 to 2,250 ml corresponding to a
cumulative dose of less than 15 ml/kg).
These data as well as the results of our study on HES
and renal function suggest that the degree of functional
impairment might depend on the HES formulation
used. In our study, in comparison to 6% HES130 and
RAc, the use of 10% HES200 was associated with a sig-
nificant lower creatinine clearance and higher creatinine
levels. Furthermore, significantly higher NAG levels in
the urine indicated a higher degree of tubular damage in
this group.
Table 3 Measured and calculated parameters of oxygenation, hemodynamics, inflammation and acid-base metabolism
6% HES 130 10% HES 200 RAc 4% gelatin SHAM
ITBV, ml/kgBW Baseline 21 ± 4 22 ± 4 23 ± 2 23 ± 4 23 ± 1
Before sepsis 22 ± 2 25 ± 5 23 ± 1 25 ± 1 24 ± 2
12 h after sepsis 24 ± 4 22 ± 5 22 ± 3 26 ± 2 24 ± 1
DO2, ml/min/kgBW Baseline 12.9 ± 2.5 14.6 ± 1.6 13.5 ± 1.4 13.2 ± 1.2 14.7 ± 0.8
Before sepsis 14.0 ± 3.1 12.5 ± 2.1 14.2 ± 1.2 15.0 ± 4.2 17.6 ± 0.6
12 h after sepsis 17.7 ± 3.0 17.8 ± 7.8 15.3 ± 3.3 14.0 ± 2.5 15.4 ± 1.8
OE % Baseline 39 ± 8 34 ± 2 36 ± 5 33 ± 6 31 ± 8
Before sepsis 31 ± 15 32 ± 5 38 ± 6 30 ± 3 31 ± 5
12 h after sepsis 37 ± 6 48 ± 8 ‡ 35 ± 9 48 ± 10 ‡ 27 ± 6
VO2 ml/min kgBW Baseline 5.3 ± 1.0 5.3 ± 0.4 5.2 ± 1.2 4.4 ± 0.6 4.8 ± 1.2
Before sepsis 4.2 ± 1.8 4.7 ± 0.8 6.1 ± 2.0 4.5 ± 1.3 5.7 ± 0.6
12 h after sepsis 7.4 ± 2.5 8.7 ± 4.5 5.2 ± 1.1 7.1 ± 1.8 4.2 ± 0.6
SvO2, % Baseline 65 ± 7 69 ± 2 67 ± 3 69 ± 7 71 ± 7
Before sepsis 74 ± 13 69 ± 7 68 ± 8 70 ± 7 70 ± 7
12 h after sepsis 62 ± 12 46 ± 9 ‡ 60 ± 14 46 ± 12 ‡ 75 ± 4
pHa Baseline 7.49 ± 0.04 7.50 ± 0.03 7.50 ± 0.05 7.50 ± 0.01 7.53 ± 0.02
Before sepsis 7.54 ± 0.03 7.51 ± 0.02 7.51 ± 0.04 7.52 ± 0.02 7.52 ± 0.03
12 h after sepsis 7.48 ± 0.04 7.27 ± 0.12 * 7.47 ± 0.07 7.38 ± 0.01 7.49 ± 0.02
BE, mmol/l Baseline 6 ± 2 6 ± 1 7 ± 3 7 ± 1 7 ± 1
Before sepsis 8 ± 1 7 ± 1 8 ± 2 9 ± 1 7 ± 1
12 h after sepsis 6 ± 1 -3 ± 5 * 7 ± 3 4 ± 6 7 ± 1
PaCO2, mm Hg Baseline 39 ± 3 38 ± 3 40 ± 3 39 ± 2 38 ± 2
Before sepsis 36 ± 3 38 ± 2 39 ± 2 39 ± 2 38 ± 3
12 h after sepsis 40 ± 6 46 ± 5 43 ± 5 46 ± 6 38 ± 2
Interleukin 10, pg/ml Baseline - - - - -
Before sepsis - - - - -
12 h after sepsis 88 ± 197 411 ± 245* 14 ± 31 296 ± 95 0 ± 0
Data are presented as mean ± SD at baseline, 6 h after hemorrhagic shock and before sepsis induction (before sepsis) and 12 h after sepsis induction. BW, body
weight; DO2, systemic oxygen delivery; HES, hydroxyethylstarch; ITBV, intrathoracic blood volume; OE, oxygen extraction ratio; PaCO2, arterial CO2; pHa, arterial
pH; BE, base excess; SvO2, mixed venous oxygen saturation; VO2, oxygen consumption. * P ≤ 0.05 vs. 6% HES130, RAc and SHAM; ‡ P ≤ 0.05 vs. SHAM.
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Our results are in line with a recent pharmacokinetic
study of healthy volunteers demonstrating that repeated
administration of 6% HES 130/0.42 shows no accumula-
tion compared to 10% HES 200/0.5 [15].
However, injury mechanisms remain unclear but the
oncotic force of the fluid replacement solutions seems
also to be important. When the oncotic pressure
exceeds the hydraulic pressure of glomerular filtration it
may suppress urine output [16]. Furthermore, glomeru-
lar filtration of hyperoncotic molecules from colloids
causes hyper viscose urine and a stasis of tubular flow,
resulting in obstruction of tubular lumen [17]. Recently,
the occurrence of renal adverse events after resuscitation
of shock in 822 ICU patients using crystalloids, hypoon-
cotic (gelatin and 4% albumin) and hyperoncotic col-
loids (HES and dextran), and hyperoncotic 20% albumin
was investigated in an observational multicenter cohort
study [18]. The occurrence of renal adverse events was
more frequent in both hyperoncotic groups compared
to crystalloids and isooncotic colloids, suggesting that
the hyperoncocity was more relevant than the nature of
the product itself. Also in our study, the COP was sig-
nificantly higher in the 10% HES200 and 4% gelatin
groups after 12 h of sepsis compared to 6% HES130 and
RAc. This might be one of the potential reasons for the
pronounced kidney injury in the 10% HES200 group.
However, as isooncotic 6% HES 130/0.42 (in vitro COP
37.8 mmHg) and hyperoncotic 10% HES 200/0.5 (in
vitro COP 80 to 85 mmHg) were compared, it cannot
be differentiated whether the oncotic force, the molecu-
lar weight, the degree of molar substitution, molecular
size, the solvent for colloid solution, or a combination
of these were determining factors of the HES-induced
adverse effects on renal function and structure.
HES is partly eliminated by the reticuloendothelial sys-
tem, and a dose dependent uptake in macrophages,
endothelial and epithelial cells was detected [19]. Addi-
tionally, tissue deposition of HES was found in the kid-
neys. The HES containing vacuoles in the kidneys are
called osmotic-like lesions (OL). This tissue deposition
of HES seems to be transitory and dose-dependent
[19,20]. In our investigation we found OL elevated in all
colloid groups achieving a significant level in the 4%
gelatin group.
In the renal histological analysis, we found in the 10%
HES200 group significantly elevated acute tubular
Table 4 Renal perfusion and function
6% HES 130 10% HES 200 RAc 4% gelatin SHAM
Left renal artery flow, ml/kgBW/min Baseline 7.0 ± 2.9 7.5 ± 2.9 6.1 ± 2.2 6.8 ± 0.4 8.3 ± 3.7
Before sepsis 5.3 ± 3.8 6.8 ± 2.6 4.6 ± 1.5 6.4 ± 0.5 8.9 ± 5.0
12 h after sepsis 9.6 ± 3.7 4.0 ± 3.1 5.0 ± 1.9 6.7 ± 2.0 11.4 ± 8.3
Crea as percentage of baseline, % Baseline - - - - -
Before sepsis 4 ± 5 12 ± 5 ‡ 10 ± 6 14 ± 6 ‡ -2 ± 2
12 h after sepsis -13 ± 7 87 ± 84**; + -4 ± 13 26 ± 13 -4 ± 13
Crea clearance, ml/min Baseline 136 ± 24 130 ± 87 108 ± 94 101 ± 46 117 ± 13
Before sepsis 98 ± 47 57 ± 36 57 ± 51 48 ± 17 78 ± 10
12 h after sepsis 97 ± 15 13 ± 14 * 76 ± 23 38 ± 8 ‡; + 98 ± 48
Urine output, ml/kgBW/h Baseline - - - - -
Before sepsis - - - - -
12 h after sepsis 3.3 ± 1.3 0.5 ± 0.3 11.5 ± 12.3 1.1 ± 0.2 2.2 ± 1.9
Cl, mmol/l Baseline 100 ± 1 100 ± 2 99 ± 2 100 ± 2 100 ± 1
Before sepsis 100 ± 1 103 ± 2 100 ± 1 98 ± 2 101 ± 2
12 h after sepsis 103 ± 2 111 ± 2 109 ± 9 98 ± 2 **; ║ 101 ± 2
Na, mmol/l Baseline 135 ± 1 135 ± 2 136 ± 2 136 ± 1 136 ± 1
Before sepsis 136 ± 2 138 ± 2 137 ± 3 138 ± 2 137 ± 1
12 h after sepsis 136 ± 2 140 ± 3 144 ± 11 138 ± 3 136 ± 2
K+, mmol/l Baseline 4.5 ± 0.4 4.4 ± 0.3 4.5 ± 0.2 4.4 ± 0.1 4.4 ± 0.2
Before sepsis 3.7 ± 0.2 3.8 ± 0.3 4.0 ± 0.2 3.9 ± 0.2 4.4 ± 0.1
12 h after sepsis 3.9 ± 0.5 5.6 ± 1.7 4.0 ± 0.3 4.9 ± 1.1 3.8 ± 0.1
Aniongap mmol/l Baseline 10.2 ± 0.8 10.0 ± 0.3 9.9 ± 1.9 10.4 ± 0.5 10.4 ± 1.4
Before sepsis 9.6 ± 0.3 9.2 ± 1.4 9.8 ± 1.3 11.4 ± 1.0 9.4 ± 1.4
12 h after sepsis 6.8 ± 0.7 10.9 ± 4.2 8.2 ± 1.2 15.4 ± 4.2**;+ 9.5 ± 0.2
Data are presented as mean ± SD at baseline, 6 h after hemorrhagic shock and before sepsis induction (before sepsis) and 12 h after sepsis induction.
BW, body weight; Cl, chloride; Crea, creatinine; K+ , potassium; Na, sodium.
* P ≤ 0.01 vs. 6% HES130, RAc and SHAM; ** P ≤ 0.05 vs. RAc; + P ≤ 0.05 vs. 6% HES130; ‡ P ≤ 0.05 vs. SHAM; ║ P ≤ 0.05 vs. 10% HES200.
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necrosis and interstitial bleeding compared to the other
groups, indicating tubular injury, thereby explaining the
increased NAG and reduced creatinine clearance.
In an ex vivo renal perfusion model, the administra-
tion of HES 130 and HES 200 solutions induced a sig-
nificant decrease in diuresis and creatinine clearance
compared with Ringer’s lactate (RL). Interestingly, 10%
HES 200/0.5 was associated in this experimental setting
with significant elevated inflammatory response in tubu-
lar monocytes. This pronounced pro-inflammatory effect
of 10% HES 200/0.5 compared with 6% HES 130/0.42
caused more tubular damage than 6% HES 130/0.42 and
RL [12]. In our present in vivo study, 10% HES200 in
comparison to 6% HES130, 4% gelatin and RAc induced
higher inflammatory response as suggested by higher Il-
6, IL-10 and TNF-a levels, which is in accordance with
our previous data. This increased inflammatory response
in the 10% HES200 group may be another explanation
for the pronounced kidney injury. In line with these
findings, Murugan et al. demonstrated a context
between elevated immune response and kidney injury
[21].
Lv et al. showed in endotoxaemic rats that 6%
HES200 in comparison to 0.9% saline reduced the
intestinal production of proinflammatory cytokines,
including TNF and IL-6 [22].
The acetate seems not to play a role in the inflamma-
tory modulation. Davies et al. found in a study of 30
adult patients undergoing cardiopulmonary bypass for
elective cardiac surgery that the use of acetate buffered
prime solutions for cardiopulmonary bypass result in
supra-physiological concentrations of acetate. Nonethe-
less, there was no difference in interleukin-6 release
compared to bicarbonate-balanced fluid [23].
Hoffmann et al. demonstrated that HES 130 is effec-
tive to prevent LPS-induced leukocyte adherence, to
attenuate LPS-induced capillary perfusion failure, and to
reduce LPS-induced macromolecular leakage indicating
even an anti-inflammatory potential of HES 130 [24].
Balanced solutions and acid-base balance
The concept of balanced fluid replacement and its rele-
vance with respect to mortality remains unclear. So far,
only limited data are available and to the best of our
Figure 3 Left renal artery flow as percentage of CO at baseline. Data are presented as mean ± standard deviation at baseline (BL), 6 h after
hemorrhagic shock and before sepsis induction (SL) and 12 h after sepsis induction * = P ≤ 0.05 vs. SHAM.
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knowledge, the present study is the first one to investi-
gate balanced fluid replacement solutions in a two-hit
model of hemorrhagic and septic shock. Resuscitation
using RAc in experimental hemorrhagic shock could
attenuate acidosis better than 0.9% saline solution,
resulting in an improved survival rate [25]. Kellum et al.
demonstrated in septic rats that the use of a balanced
Hextend solution in comparison with 0.9% saline solu-
tion was associated with improved acid balance and
even survival [10]. In line with Kellums data, we found
that using 6% HES 130/0.42 in RAc and RAc resulted in
significantly less negative base excess than resuscitation
using 10% HES 200/0.5 in 0.9% saline. The administered
amount of the latter was less compared to RAc. This
result indicates that solvent for colloid solutions may be
of relevance in resuscitation of shock in order to avoid
further acid-based derangements. Interestingly, we could
not find any differences in the concentration of chloride
and sodium in the blood, except for a significantly lower
chloride level in the 4% gelatin group at study end, most
likely due to the fact that 4% gelatin contains less chlor-
ide than RAc (4% gelatin 85 mmol/l; RAc 112 mmol/l).
This is also reflected in a significantly higher calculated
anion gap in the 4% gelatin group; the anion gap did
not change in all other groups compared to baseline.
Thus, the use of 0.9% saline as a solvent was not asso-
ciated with unwanted electrolyte disturbances in our
model.
Furthermore, it was not possible to prevent metabolic
acidosis in the 10% HES 200 group with no change in
the anion gap compared to baseline. The metabolic
acidosis in the 10% HES 200/0.5 group may be in part
explained by the elevated chloride levels (111 ± 2
Figure 4 N-acetyl-beta-D-glucosamidase in urine as a marker of lysosomal tubular damage. Data are presented as mean ± standard
deviation in Units per gram creatinine at baseline (BL), 6 h after hemorrhagic shock and before sepsis induction (SL) and 12 h after sepsis
induction * = P ≤ 0.05 vs. 6% HES130, RAc und SHAM.
Table 5 Histopathological scoring of kidneys
6% HES 130 10% HES 200 RAc 4% gelatin SHAM
Ol 1.0 ± 0.9 1.5 ± 1.0 0.3 ± 0.3 2.6 ± 0.5* 0.5 ± 0.0
ATN 1.8 ± 1.1 2.2 ± 0.4‡ 0.8 ± 0.3 2.6 ± 0.5‡** 0.3 ± 0.6
IBl 0.4 ± 0.5 1.6 ± 0.9* 0.3 ± 0.5 0.6 ± 0.4 0.0 ± 0.0
GSl 1.3 ± 1.0 1.4 ± 0.5 0.6 ± 0.3 1.1 ± 0.5 0.7 ± 0.3
Histopathological scoring of osmotic nephrosis-like lesions (OL), acute tubulus
necrosis (ATN), interstitial bleeding (IBl) and glomerular sclerosis (GSl). * P ≤
0.01 vs. 6% HES130, RAc and SHAM ** P ≤ 0.05 vs. RAc; ‡ P ≤ 0.05 vs. SHAM
Data are presented as mean ± standard deviation.
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mmol/l) due to the carrier solution. In addition, acetate
is metabolized to HCO3
- in the other solutions and is
acting as a buffer in situ.
Limitations
A limitation of our model may be the experimental
duration of 19 hours. On the other hand, Rivers et al.
have shown that early goal-directed fluid resuscitation in
patients with severe sepsis and septic shock provides
significant benefits related to outcome in the first six
hours after admission to an accident and emergency
hospital (A&E) [2].
We chose CVP as our target for the infusion of the
fluid replacement solutions according to the Surviving
Sepsis Campaign: International guidelines for manage-
ment of severe sepsis and septic shock [3]. Nevertheless
there are several studies in critically ill patients [26,27]
suggesting that ITBV is a valuable preload indicator. In
our study, the data of ITBV suggest sufficient fluid sta-
tus until the end of the experiment.
Another potential confounding factor may be gender
differences in the inflammatory response and survival in
sepsis [28]. Ovariectomized mice had a higher death rate
than proestrus mice after cecal ligation and puncture
[29]. This potential difference could not be addressed in
our study because we used female pigs only.
Conclusions
Despite similar maintenance of macrocirculation 6%
hydroxyethylstarch 130/0.42 and Ringer’s acetate signifi-
cantly preserve renal function and attenuate tubular
damage better than 10% hydroxyethylstarch 200/0.5 in
saline.
Key messages
• After resuscitation there was no difference in sys-
temic hemodynamics comparing the investigated
solutions.
• Ten percent HES 200/0.5 induced significant
increased tubular damage compared to Ringers’s
acetate and 6% HES 130/0.42.
• Ten percent HES 200/0.5 induced significant renal
impairment compared to Ringers’s acetate and 6%
HES 130/0.42.
Additional material
Additional file 1: Histological analysis of an animal kidney treated
with 10%HES200. The Sections (4 μm) were cut and stained with
hematoxylin and eosin. Osmotic-nephrosis like lesions are widespread
and marked with an arrow. Original magnification: × 200.
Additional file 2: Histological analysis of an animal kidney SHAM
treated. The Sections (4 μm) were cut and stained with hematoxylin and
eosin. Osmotic-nephrosis like lesions are very rare. Original magnification:
× 200.
Additional file 3: Histological analysis of an animal kidney treated
with10% HES200. The Sections (4 μm) were cut and stained with
hematoxylin and eosin. Interstitial bleeding are marked with an arrow.
Original magnification: × 200.
Abbreviations
10% HES200: 10% hydroxyethylstarch 200/0.5 in saline; 4% gelatin: 4%
gelatin in acetate; 6% HES 130: 6% hydroxyethylstarch 130/0.42; ATN: acute
tubular necrosis; BL: baseline; BW: body weight; CFU: colony forming units;
CO: cardiac output; COP: colloid osmotic pressure; CrCl: Creatinine clearance;
CVP: central venous pressure; DO2, systemic oxygen delivery; GSl: glomerulo
sclerosis; Hct: hematocrit; HES: hydroxyethyl starch; Ibl: interstitial bleeding;
IL-10: Interleukin 10; IL-6: Interleukin 6; ITBV: Intrathoracic blood volume;
MAP: mean arterial pressure; MPAP: mean pulmonary artery pressure; NAG:
N-acetyl- beta-D-glucosamidase; OE: oxygen extraction ratio; OL: osmotic-
nephrosis like lesions; PAOP: pulmonary artery occlusion pressure; PEEP:
positive end-expiratory pressure; Rac: Ringer’s acetate; RBF: Renal blood flow;
RL: Ringer’s lactate; SD: standard deviation; SHAM: sham-treated group; TNF-
α: tumor necrosis factor alpha; VISEP: efficacy of fluid substitution and insulin
therapy in severe sepsis.
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